| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
Purity: ≥98%
Umbelliferone (also known as 7-Hydroxycoumarin, Hydrangin or Skimmetin) is a natural product of the coumarin class, it is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone modulates the oxidative metabolism, degranulation and microbial killing of human neutrophils. Umbelliferone acts on neutrophils to produce relevant anti-inflammatory effects
| ln Vitro |
Umbelliferone exhibited a dose- and time-dependent reduction in viability of HepG2 human hepatocellular carcinoma (HCC) cells, as determined by MTT assay after treatment for 12, 24, and 48 hours with concentrations ranging from 1 to 50 µM. The half-maximal inhibitory concentration (IC50) values were obtained from the MTT viability curves, but specific numerical values are not provided in the text or Figure 1.
Treatment of HepG2 cells with umbelliferone (5, 25, 50 µM for 24 hours) induced characteristic morphological changes of apoptosis, including cell shrinkage and membrane blebbing, as observed under an inverted light microscope. Acridine orange/ethidium bromide (AO/EB) double-staining of HepG2 cells treated with umbelliferone (5, 25, 50 µM for 24 hours) showed a reduction in cells with large nuclei and the appearance of nuclear condensation and apoptotic body formation at the highest concentration (50 µM). Flow cytometric cell cycle analysis using propidium iodide (PI) staining showed that treatment with umbelliferone (5, 25, 50 µM for 48 hours) induced S-phase arrest in HepG2 cells. The percentage of cells in S phase increased from 43.6% (untreated) to 45.0%, 51.3%, and 62.1% at 5, 25, and 50 µM, respectively. Concomitantly, the G1 phase population decreased. Annexin V/PI staining and flow cytometry analysis revealed that umbelliferone (5, 25, 50 µM for 48 hours) induced apoptosis in HepG2 cells in a dose-dependent manner, with a notable increase in early apoptotic events. A DNA fragmentation assay demonstrated that treatment of HepG2 cells with umbelliferone (5, 25, 50 µM for 72 hours) induced pronounced DNA laddering, a hallmark of apoptosis, whereas untreated control cells did not. |
|---|---|
| Cell Assay |
Cell Viability Assay (MTT): HepG2 cells were treated with umbelliferone at various concentrations (1, 2, 5, 25, 50 µM) for 12, 24, or 48 hours. After treatment, MTT solution was added to each well and incubated for 3 hours. The supernatant was then removed, dimethyl sulfoxide was added to dissolve the formazan crystals, and the absorbance was measured at 570 nm using a microplate reader. Wells without cells served as blanks. The half-maximal inhibitory concentration (IC50) values were calculated from the resulting viability curves.
Morphological Analysis: HepG2 cells were plated and treated with various concentrations of umbelliferone (0, 5, 25, 50 µM) for 24 hours. Cells were then examined and imaged using an inverted light microscope to observe morphological changes. Separately, cells on coverslips were treated similarly, washed, stained with acridine orange and ethidium bromide solution, and examined under a fluorescence microscope. Cell Cycle Analysis: HepG2 cells were treated with umbelliferone (0, 5, 25, 50 µM) for 48 hours. Cells were then collected, washed, fixed with 70% alcohol, and stained with propidium iodide in the presence of RNase A. The DNA content and cell cycle distribution were analyzed using flow cytometry. Apoptosis Detection by Flow Cytometry: HepG2 cells were treated with umbelliferone (0, 5, 25, 50 µM) for 48 hours. Cells were collected, washed, and stained with Annexin V-FITC and propidium iodide according to the kit instructions. The stained cells were then analyzed by flow cytometry to differentiate between viable, early apoptotic, late apoptotic, and necrotic cell populations. DNA Fragmentation Assay: HepG2 cells were treated with umbelliferone (5, 25, 50 µM) for 72 hours. Cells were harvested, washed, and lysed. The lysate was treated with RNase A and proteinase K. DNA was precipitated with cold ethanol after the addition of ammonium acetate, collected by centrifugation, dissolved in loading buffer, and separated by electrophoresis on a 1% agarose gel. DNA fragments were visualized under UV light after ethidium bromide staining. |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
7-Hydroxycoumarin is a known human metabolite of 7-ethoxycoumarin, 7-methoxycoumarin, and coumarin. |
| References | |
| Additional Infomation |
Umbelliferone is a hydroxycoumarin with a structure in which coumarin is replaced by a hydroxyl group at the 7-position. It can be used as a fluorescent probe, plant metabolite, and food ingredient. Umbelliferone has been reported to exist in hydrangea, caragana, and other organisms with relevant data. See also: chamomile (partial). Umbelliferone, also known as 7-hydroxycoumarin, is a naturally occurring coumarin derivative that can be isolated from plants such as asafoetida. It is a yellowish-white crystalline solid. This study indicates that, to the authors' knowledge, this is the first report investigating the anticancer activity of umbelliferone against HepG2 liver cancer cells and its mechanism of action. The results suggest its potential application value in liver cancer treatment, but further verification is needed. The introduction and discussion sections mention that other studies (not cited in this article) have reported various biological activities of umbelliferone, including its use in sunscreens, and it has shown analgesic, anti-inflammatory, bronchodilation, and antitumor effects in other models. However, according to the literature extraction rules, this article does not include such information from other literature.
|
| Molecular Formula |
C9H6O3
|
|---|---|
| Molecular Weight |
162.1421
|
| Exact Mass |
162.031
|
| CAS # |
93-35-6
|
| Related CAS # |
Umbelliferone-d5;1215373-23-1
|
| PubChem CID |
5281426
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
382.1±37.0 °C at 760 mmHg
|
| Melting Point |
230 °C (dec.)(lit.)
|
| Flash Point |
181.2±19.3 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
1.58
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ORHBXUUXSCNDEV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H
|
| Chemical Name |
7-Hydroxycoumarin
|
| Synonyms |
7-Hydroxycoumarin; 7-Hydroxylcoumarin; 7-Oxycoumarin; Hydrangin; Hydrangine; NSC 19790; NSC-19790; NSC19790; Skimmetin; Skimmetine; Umbelliferon;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 14.29 mg/mL (~88.13 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.43 mg/mL (8.82 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.43 mg/mL (8.82 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1675 mL | 30.8375 mL | 61.6751 mL | |
| 5 mM | 1.2335 mL | 6.1675 mL | 12.3350 mL | |
| 10 mM | 0.6168 mL | 3.0838 mL | 6.1675 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA